Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure: The MOMENTUM Trial

Journal of Cardiac Failure

Volumn 13, Issue 9, 2007, Pages 715-721

  Greenberg, Barry ^a   Czerska, Barbara ^b   Abraham, William T ^c   Neaton, James D ^d   Delgado, Reynolds M ^e   Mather, Paul ^f   Bourge, Robert ^g   Parker, Irene C ^h   Konstam, Marvin A ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e TEXAS HEART INSTITUTE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Orqis Medical   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

Author keywords

Continuous aortic flow augmentation; heart failure; heart assist device; hemodynamics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ADULT; AGED; AORTA FLOW; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AORTA; BLOOD FLOW VELOCITY; DISEASE PROGRESSION; EXTRACORPOREAL CIRCULATION; HEALTH STATUS INDICATORS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; PERIPHERAL VASCULAR DISEASES; STROKE VOLUME; TREATMENT FAILURE;

EID: 35748967269     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.06.728     Document Type: Article

References (33)

1. American Heart Association 2004. Heart disease and stroke statistics-2004 update. Dallas, TX: American Heart Association. Available at: www.americanheart.org. Accessed July 28, 2004.
2. Krumholz H.M., Parent E.M., Tu N., Vaccarino V., Wang Y., Radford M.J., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
3. Jain P., Massie B.M., Gattis W.A., Klein L., and Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J 145 (2003) S3-S17
4. Frazier O.H., Rose E.A., Oz M.C., Dembitsky W., McCarthy P., Radovancevic B., et al. HeartMate Investigators. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122 (2001) 1186-1195
5. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
6. Haithcock B.E., Morita H., Fanous N.H., Suzuki G., and Sabbah H.N. Hemodynamic Unloading of the failing left ventricle using an arterial-to-arterial extracorporeal flow circuit. Ann Thorac Surg 77 (2004) 158-163
7. Gharib M., and Beizaie M. Correlation between negative near-wall shear stress in human aorta and various stages of congestive heart failure. Ann Biomed Eng 3 (2003) 678-685
8. Lu X., and Kassab G.S. Nitric oxide is significantly reduced in ex-vivo porcine arteries during reverse flow because of increased superoxide production. J Physiol 561 Pt 2 (2004) 575-582
9. Konstam M.A., Czerska B., Böhm M., Oren R.M., Sadowski J., Khanal S., et al. Continuous aortic flow augmentation: hemodynamic and renal responses to a novel percutaneous intervention in patients with decompensated heart failure. Circulation 112 (2005) 3107-3114
10. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
11. Mahon N.G., Blackstone E.H., Francis G.S., Starling III R.C., Young J.B., and Lauer M.S. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 40 (2002) 1106-1113
12. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
13. Gould A.L. Sample size re-estimation: recent developments and practical considerations. Stat Med 20 (2001) 2625-2643
14. Yamamoto K., Burnett Jr. J.C., Jougasaki M., Nishimura R.A., Bailey K.R., Saito Y., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
15. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
16. Erlandsen E.J., Randers E., and Kristensen J.H. Evaluation of the Dade Behring N Latex Cystatin C Assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 59 (1999) 1-8
17. Moshage H., Kok B., Huizenga J., and Jansen L. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 6 (1995) 892-896
18. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., and Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
19. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., and Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42 (2003) 705-708
20. Cotter G., Metzkor E., Kaluski E., Faigenberg Z., Miller R., Simovitz A., et al. Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet 351 (1998) 389-393
21. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
22. Cuffe M.S., Califf R.M., Adams Jr. K.F., Benza R., Bourge R., Colucci W.S., et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
23. O'Connor C.M., Gattis W.A., Uretsky B.F., Adams Jr. K.F., McNulty S.E., Grossman S.H., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flora International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
24. Bouvy M.L., Heerdink E.R., De Bruin M.L., Herings R.M., Leufkens H.G., and Hoes A.W. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 160 (2000) 2477-2480
25. Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., et al., for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
26. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., et al., for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
27. Bart B.A., Boyle A., Bank A.J., Anand I., Olivari M.T., Kraemer M.D., et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 46 (2005) 2043-2046
28. Al-Ahmad A., Rand W.M., Manjunath G., Konstam M.A., Salem D.N., Levey A.S., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
29. Weinfeld M.S., Chertow G.M., and Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138 (1999) 285-290
30. Aronson D., Mittleman M.A., and Burger A.J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116 (2004) 466-473
31. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
32. Shah M.R., Stinnett S.S., McNulty S.E., Gheorghiade M., Zannad F., Uretsky B., et al. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Am Heart J 141 (2001) 908-914
33. Fonarow G.C. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2 Suppl 2 (2001) S7-S12